Krystal Biotech, Inc. (KRYS)

157,68 -4,08 (-2,52%) Al cierre: 04:00PM EDT

Krystal Biotech, Inc.

2100 Wharton Street
Suite 701
Pittsburgh, PA 15203
United States
412 586 5830
https://www.krystalbio.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 229

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. Krish S. Krishnan M.B.A., M.S.	Founder, Chairman, President & CEO	1,32M	N/A	1965
Ms. Suma M. Krishnan	Founder, President of R&D and Director	895,33k	N/A	1965
Ms. Kathryn A. Romano	Executive VP & Chief Accounting Officer	614,87k	2,35M	1982
Mr. John Thomas	General Counsel & Corporate Secretary	N/A	N/A	N/A
Mr. John Karakkal	Vice President of North American Sales & Marketing	N/A	N/A	N/A
Ms. Christine Wilson	Head of U.S. Sales and Marketing	N/A	N/A	N/A
Mr. Josh Suskin	Director of Human Resources & Operations	N/A	N/A	N/A
Mr. Laurent Goux	Senior VP & GM of Europe	N/A	N/A	N/A
Mr. David Chien	Senior Vice President of Clinical Development	N/A	N/A	N/A
Ms. Jennifer McDonough	SVP of Patient Access, Analytics & Operations	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Gobierno corporativo

El ISS Governance QualityScore de Krystal Biotech, Inc., a día 1 de mayo de 2024, es 6. Las puntuaciones base son Auditoría: 2; Tablero: 8; Derechos de los accionistas: 8; Compensación: 5.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.